TEXCELL, a supplier of services in viral security, immunology and toxicology for the past 20 years, is now a « Pharmaceutical Establishment » meeting Good Manufacturing Practice (GMP) requirements for its viral security and immunological analyses.
Thanks to its experience in the creation of biosecurity tests and viral validations, Texcell has already evaluated a large number of products, some of which are now registered internationally by various authorities (ANSM, FDA, EMA, MHW…)
« In order to satisfy the requirements of the world pharmaceutical industry, TEXCELL, which has been committed to compliance with good laboratory practice since 2003, has been inspected and certified BPL by ANSM (National Drug Security Agency).
Furthermore, since 2013 TEXCELL has undertaken a development programme aimed at becoming a pharmaceutical establishment for quality control conforming with good manufacturing practice (GMP) for its virological and immunological analyses, » according to TEXCELL President and CEO Bernard Plichon.
With TEXCELL’s structure now modified to meet pharmaceutical regulations (GMP and public health code), the company has appointed a chief pharmacist: Monique Maire, director of quality and assistant managing director, as well as an interim pharmacist.
« TEXCELL staff have made great efforts in the last three years to achieve this level of quality and significant financial investment has enabled us to satisfy GMP regulatory demands, » says Monique Maire.
« Reaching this objective will allow Texcell to strengthen confidence among its existing European pharmaceutical customers. And it will be able to convince future customers to entrust their analyses to us, with certification of the results by our chief pharmacist, » according to Grégoire Tauveron, European export director.
« With TEXCELL now offering a range of certified services, this development will consolidate our key accounts in France and abroad in the long term, » adds Yves Barbier, commercial and marketing director.
TEXCELL continues to develop internationally, first with the acquisition in 2010 of a majority stake in an American company based in Middletown (MD), now Texcell North America. In early 2016 TEXCELL expanded its commercial partnerships in Asia, in particular in South Korea and more recently in Taiwan with ATRI (Agricultural Technology Research Institute). It also bought Vivo Science, a German company based in Gronau and specialising in toxicology, immunology and virology in vivo studies (GMP).
TEXCELL is based at Evry’s Genopole Biocluster near Paris and has more than 2500 m2 of offices and laboratories (L2 & L3). It provides a wide range of services in viral safety and immunological tracking in compliance with Good Laboratory Practice and Good Manufacturing Practice.
Head office : Campus 3 – Bât. Genavenir 5 – 1, rue Pierre Fontaine – F-91058 Evry cedex – France
The first biocluster in France dedicated to research in genetics and biotechnologies applied to health and the environment, Genopole has brought together 82 biotechnology companies, 19 research laboratories and 25 technology platforms as well as university courses (University of Evry-Val-d’Essonne). Its aim is to create and support biotechnology companies and the transfer of technologies to the industrial sector, to encourage the growth of research in life sciences and the development of high-level teaching in these areas.
Genopole is principally financed by the state and the region of Ile-de-France.